Kun Kim | Karolinska Institutet

Om mig
Publikationer
CV
Populärvetenskap och samverkan

Om mig

Jag är hälsoekonom och forskar främst inom ekonomiska utvärderingar av nya läkemedel. Jag är speciellt intresserad av överlevnadsextrapoleringar för patienter inom onkologi. Mer information hittas på den engelska versionen av denna sida.

Artiklar

Article: THORACIC CANCER. 2025;16(1):e15535
Long-Term Real-World Survival of Immunotherapy Compared to Chemotherapy for Metastatic Nonsmall Cell Lung Cancer: A Propensity Score-Matched Analysis
Kim K; Sweeting M; Jonsson L; Wilking N
Journal article: MEDICAL DECISION MAKING. 2024;44(7):843-853
General Population Mortality Adjustment in Survival Extrapolation of Cancer Trials: Exploring Plausibility and Implications for Cost-Effectiveness Analyses in HER2-Positive Breast Cancer in Sweden
Kim K; Sweeting M; Wilking N; Joensson L
Journal article: BMC NEPHROLOGY. 2022;23(1):281
Cost effectiveness of sodium zirconium cyclosilicate for the treatment of hyperkalaemia in patients with CKD in Norway and Sweden
Kim K; Fagerstrom J; Chen G; Lagunova Z; Furuland H; McEwan P
Journal article: BMJ OPEN. 2019;9(4):e026465
Healthcare resource utilisation and cost associated with elevated potassium levels: a Danish population-based cohort study
Kim K; Thomsen RW; Nicolaisen SK; Hasvold LP; Palaka E; Sorensen HT
Journal article: OPHTHALMIC RESEARCH. 2017;58(1):49-55
Identifying Predictors of Anti-VEGF Treatment Response in Patients with Neovascular Age-Related Macular Degeneration through Discriminant and Principal Component Analysis
Holz FG; Tadayoni R; Beatty S; Berger AR; Cereda MG; Hykin P; Hoyng CB; Wittrup-Jensen K; Altemark A; Nilsson J; Kim K; Sivaprasad S
Journal article: EYE. 2016;30(8):1063-1071
Determinants of visual acuity outcomes in eyes with neovascular AMD treated with anti-VEGF agents: an instrumental variable analysis of the AURA study
Holz FG; Tadayoni R; Beatty S; Berger AR; Cereda MG; Hykin P; Staurenghi G; Wittrup-Jensen K; Nilsson J; Kim K; Sivaprasad S
Article: OSTEOPOROSIS INTERNATIONAL. 2014;25(1):325-337
Comparative cost-effectiveness of bazedoxifene and raloxifene in the treatment of postmenopausal osteoporosis in Europe, using the FRAX algorithm
Kim K; Svedbom A; Luo X; Sutradhar S; Kanis JA
Journal article: JOURNAL OF THORACIC ONCOLOGY. 2013;8(8):997-1003
Health-Related Quality of Life and Utility in Patients with Advanced Non-Small-Cell Lung Cancer: A Prospective Cross-Sectional Patient Survey in a Real-World Setting
Chouaid C; Agulnik J; Goker E; Herder GJM; Lester JF; Vansteenkiste J; Finnern HW; Lungershausen J; Eriksson J; Kim K; Mitchell PLR
Article: HEAD AND NECK ONCOLOGY. 2011;3:47
Economic burden of resected squamous cell carcinoma of the head and neck in an incident cohort of patients in the UK
Kim K; Amonkar MM; Hogberg D; Kasteng F

Alla övriga publikationer

Thesis / dissertation: KAROLINSKA INSTITUTET. 2025
Predictive extrapolation : A framework to reduce uncertainty around long-term treatment effects of innovative cancer therapies
Kim K
Thesis / dissertation: KAROLINSKA INSTITUTET. 2025
Predictive extrapolation : a framework to reduce uncertainty around long-term treatment effects of innovative cancer therapies
Kim K
Doctoral thesis: 2025
Predictive extrapolation : a framework to reduce uncertainty around long-term treatment effects of innovative cancer therapies
Kim K
Conference publication: VALUE IN HEALTH. 2023;26(12):S103
EE268 Healthcare Costs and All-Cause Mortality Following a Hyperkalemia Event and Reduction of RAASi Therapy in Sweden
Svensson MK; Kim K; Cars T; Rao N; Lesén E; Jarbrink K
Conference publication: ANNALS OF ONCOLOGY. 2023;34:s833-s834
Immunotherapy prolongs long-term real-world survival compared to chemotherapy for metastatic non-small cell lung cancer: A propensity score-matched analysis
Kim K; Sweeting M; Wilking N; Jonsson L
Conference publication: VALUE IN HEALTH. 2016;19(7):A655
TICAGRELOR TREATMENT FOR PREVENTION OF CARDIOVASCULAR EVENTS IN HIGH RISK POST MYOCARDIAL INFARCTION PATIENTS: COST-EFFECTIVENESS ANALYSIS USING EVIDENCE FROM THE PEGASUS-TIMI 54 TRIAL
Moore P; Briggs A; Davies A; Sculpher M; Kun K; Magnuson EA; Cohen DJ; Mellstrom C
Conference publication: VALUE IN HEALTH. 2013;16(7):A413
COST-EFFECTIVENESS OF CABAZITAXEL IN MHRPC IN TURKEY
Yesil A; Sahin T; De Geer A; Kim K; Topcu T
Review: INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER. 2013;23(5):823-832
Treatment Patterns, Health Care Utilization, and Costs of Ovarian Cancer in Central and Eastern Europe Using a Delphi Panel Based on a Retrospective Chart Review
Kim K; Hernlund E; Hernadi Z; Revesz J; Pete I; Szantho A; Bodnar L; Madry R; Timorek-Lemieszczuk A; Bozanovic T; Vasovic S; Tomasevic Z; Zivaljevic M; Pazin V; Minarik T; Garanova H; Helpianska L; Justo N
Conference publication: VALUE IN HEALTH. 2012;15(7):A417-A418
TREATMENT PATTERNS, HEALTH CARE UTILIZATION, AND COSTS OF OVARIAN CANCER IN CENTRAL AND EASTERN EUROPE USING A DELPHI PANEL BASED ON A RETROSPECTIVE CHART REVIEW
Kim K; Hernlund E; Justo N; Hernadi Z; Pete I; Revesz J; Szantho A; Bodnar L; Madry R; Timorek-Lemieszczuk A; Bozanovic T; Vasovic S; Tomasevic Z; Zivaljevic M; Pazin V; Minarik T; Garanova H; Helpianska L
Conference publication: JOURNAL OF CLINICAL ONCOLOGY. 2011;29(15):5540
Clinical characteristics of an incident cohort of patients with resected squamous cell carcinoma of the head and neck (SCCHN) in the United Kingdom.
Kim K; Amonkar M; Hogberg D; Kasteng F
Conference publication: VALUE IN HEALTH. 2011;14(3):a162
HEALTH CARE UTILIZATION AND COSTS OF RESECTED SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK (SCCHN) IN AN INCIDENT COHORT OF PATIENTS IN THE UNITED KINGDOM
Kim K; Amonkar M; Hoegberg D; Kasteng F
Conference publication: VALUE IN HEALTH. 2010;13(7):a256
EPIDEMIOLOGY AND HEALTH-CARE UTILIZATION FOR RESECTED SQUAMOUS CELL CARCINOMA OF HEAD AND NECK (SCCHN) IN SOUTH KOREA
Kim K; Amonkar M; Lykopoulos K; Kasteng F; Hogberg D

Anställningar

Anknuten till Forskning, Neurobiologi, vårdvetenskap och samhälle, Karolinska Institutet, 2023-2025

Examina och utbildning

Medicine Doktorsexamen, Institutionen för neurobiologi, vårdvetenskap och samhälle, Karolinska Institutet, 2025

Nyheter från KI

Kalenderhändelser från KI